Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | PDE8B | O95263 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842356 | 1.00 | ATM (0.50) | ATMPDE8BHPGDKDM1AEPHX1 | |
| SCHEMBL1551631 | 0.98 | ATM (0.51) | ATMPDE8BHPGDKDM1AEPHX1 | |
| SCHEMBL2354644 | 0.98 | ATM (0.51) | ATMPDE8BHPGDKDM1AEPHX1 | |
| SCHEMBL2345014 | 0.98 | ATM (0.51) | ATMPDE8BHPGDKDM1AEPHX1 | |
| SCHEMBL639097 | 0.94 | ATM (0.49) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL3420227 | 0.94 | ATM (0.49) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL115698 | 0.94 | ATM (0.49) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL29551106 | 0.90 | ATM (0.47) | ATMPDE8BHPGDKDM1AEPHX1 | |
| SCHEMBL3422188 | 0.90 | ATM (0.47) | ATMPDE8BHPGDKDM1AEPHX1 | |
| SCHEMBL29550329 | 0.90 | ATM (0.47) | ATMPDE8BHPGDKDM1AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794129-B1 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-30 | — | — | EP | disclosed |
| EP-1794129-B1 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-30 | — | — | EP | disclosed |
| EP-1794129-A4 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-02 | — | — | EP | disclosed |
| US-7402670-B2 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| US-7402670-B2 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| US-7402670-B2 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| EP-1794129-A2 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006039383-A2 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | DENG XIAOHU | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | SRM, SMOX, DDC | ATM 3394/4885PDE8B 4711/4885HPGD 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.